低分子肝素复合丹红注射液在门脉高压症脾切除术后的早期应用-普外科专业论文.docxVIP

万方数据 万方数据 目 录 中文摘要···································································································1 英文摘要·····································································································3 英文缩写·····································································································6 研究论文 低分子肝素复合丹红注射液在门脉高压症脾切除术后的早期 应用 前言······································································································7 资料与方法································································································9 结果······································································································12 附表··································································································14 讨论···································································································17 结论·····························································································24 参考文献··························································································25 综述································································································28 致谢··································································································38 个人简介····································································································39 中 中 文 摘 要 PAGE 1万方数据 PAGE 1 万方数据 低分子肝素复合丹红注射液在门脉高压症脾切除术后的 早期应用 摘 要 目的：门静脉高压症（portal hypertension PHT）为肝硬化失代偿期的 突出临床表现，常常累计诸多器官，可能出现的症状主要有脾脏的病理性 增大，伴或不伴脾功能亢进，凶险性上消化道出血，肝性脑病，肝肾综合 征，肝肺综合征等一系列临床表现。在肝硬化失代偿期的治疗方面，主要 是并发症（主要是食管-胃底静脉曲张）的治疗。然而，门静脉血栓（portal vein thrombosis PVT）的形成降低了患者预后以及生存质量。门静脉血栓 形成是肝硬化门脉高压症脾切除术的常见术后并发症，尤其是多见于分流 术，断流术，肝移植术后，因此，为门静脉血栓制定早预防，早发现、早 治疗的方案非常重要。本研究通过总结和分析我科近两年来通过行门脉高 压症脾切除术后低分子肝素复合丹红注射液在术后的早期应用的临床效 果，为以后的术后临床用药提供指导意义。 方法：收集自 2014 年 2 月至 2015 年 12 月在河北医科大学第二医院 肝胆外科收住院肝硬化合并门脉高压症行脾切除联合贲门周围血管离断 术的患者，并且有完整病例资料的患者共 106 例，随机分试验组及对照组： 试验组 49 例，其中男性 30 例，女性 19 例，年龄 30-66 岁（37±10.